These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23185925)

  • 1. [Are we ready to prescribe a polypill to our patients?].
    Castioni J; Mooser V; Waeber G
    Rev Med Suisse; 2012 Oct; 8(360):2046, 2048-51. PubMed ID: 23185925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
    Wald DS; Wald NJ
    J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The polypill: a potential global solution to cardiovascular disease.
    Nguyen C; Cheng-Lai A
    Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The polypill in the primary prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Fundam Clin Pharmacol; 2010 Feb; 24(1):29-35. PubMed ID: 20002198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health. Experts debate polypill: a single pill for global health.
    Reardon S
    Science; 2011 Sep; 333(6051):1813. PubMed ID: 21960602
    [No Abstract]   [Full Text] [Related]  

  • 11. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
    Sanz G; Fuster V; Guzmán L; Guglietta A; Arnáiz JA; Martínez F; Sarria A; Roncaglioni MC; Taubert K
    Am Heart J; 2011 Nov; 162(5):811-817.e1. PubMed ID: 22093195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
    Stirban AO; Tschoepe D
    Diabetes Care; 2008 Feb; 31 Suppl 2():S226-8. PubMed ID: 18227490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular polypill in high risk patients].
    Lafeber M; Spiering W; Bots ML; de Valk V; Visseren FL; Grobbee DE
    Ned Tijdschr Geneeskd; 2011; 155(44):A3070. PubMed ID: 22067559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular prevention: could the polypill reduce the risk of clinical inertia and poor compliance?].
    Scheen AJ; Lefebvre PJ; Kulbertus H
    Rev Med Liege; 2010; 65(5-6):267-72. PubMed ID: 20684405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.